SNORA36A: A Small Nucleolar RNA with Potential as a Drug Target or Biomarker

Target Name: SNORA36A

NCBI ID: G677817

SNORA36A

Other Name(s): Small nucleolar RNA, H/ACA box 36A | small nucleolar RNA, H/ACA box 36A | ACA36

SNORA36A: A Small Nucleolar RNA with Potential as a Drug Target or Biomarker

Small nucleolar RNA (snRNA), also known as microRNA (miRNA), is a non-coding RNA molecule that plays a crucial role in regulating gene expression in eukaryotic cells. One of the key functionalities of snRNAs is their ability to interact with mRNAs to either promote or repress their translation into proteins. The H/ACA box is a specific type of snRNA that is expressed in high levels in various tissues and is involved in the regulation of various cellular processes. In this article, we will focus on SNORA36A, a H/ACA box snRNA that has been identified as a potential drug target or biomarker.

SNORA36A is a 24.1 kilobase (kb) RNA molecule that is found in various tissues, including the brain, heart, liver, and muscle. It is expressed at levels of up to 10% of total cellular RNA and is involved in the regulation of various cellular processes, including cell growth, apoptosis, and inflammation. The H/ACA box is a specific region of the snRNA that is located between the 5' and 3' ends of the molecule. It is composed of 76 amino acid residues and is involved in the formation of a stem-loop structure.

SNORA36A has been shown to play a role in the regulation of cellular processes by interacting with various target mRNAs. One of the well-studied targets of SNORA36A is the protein heat shock protein (HSP70), which is a chaperone that helps to protect cells from the harmful effects of heat stress. Several studies have shown that SNORA36A can interact with HSP70 and promote the expression of HSP70 genes, thereby contributing to the regulation of cellular processes.

Another target of SNORA36A is the transcription factor p53, which is a well-known regulator of cellular apoptosis. Several studies have shown that SNORA36A can interact with p53 and promote the expression of p53 genes, thereby contributing to the regulation of apoptosis ( 6).

In addition to its role in the regulation of cellular processes, SNORA36A has also been shown to play a role in the development and progression of certain diseases. For example, several studies have shown that SNORA36A is downregulated in various tissues of cancer cells and that its expression is associated with the poor prognosis of cancer patients.

Based on these findings, SNORA36A has been identified as a potential drug target or biomarker for various diseases. Researchers are currently working to develop small molecule inhibitors of SNORA36A as a potential therapeutic approach for the treatment of various diseases, including cancer.

In conclusion, SNORA36A is a small nucleolar RNA that plays a crucial role in regulating cellular processes and has been shown to interact with various targets, including HSP70 and p53. Its expression is involved in the regulation of cellular growth, apoptosis, and inflammation, and Its downregulation is associated with the development and progression of certain diseases. As a potential drug target or biomarker, SNORA36A is a promising target for the development of new therapeutic approaches for various diseases.

Protein Name: Small Nucleolar RNA, H/ACA Box 36A

The "SNORA36A Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SNORA36A comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets